Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil is highly toxic to pets, especially cats and dogs, even in small amounts. Many users have switched to oral minoxidil to prevent accidental exposure to their pets.

The user started using 5% minoxidil foam in February and experienced shedding a few weeks later, which continued for about twelve weeks. They are also taking pumpkin seed oil and saw palmetto but remain skeptical about their effectiveness.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

A user with mild psoriasis on the scalp is using finasteride, topical minoxidil, and dermarolling for hair loss but plans to stop minoxidil on the crown due to psoriasis aggravation. Suggestions include switching to a lipid-based minoxidil, using Ketoconazole shampoo, or trying oral minoxidil.

A user's progress with hair regrowth after 3 months of using 1 mg finasteride and 5 mg minoxidil orally, despite some skepticism from other users. The user reports having low blood pressure and feeling fatigued as side effects, but others suggest switching to topical minoxidil for better results with less risk.

The user is using oral Minoxidil 2.5 mg, oral Finasteride 1 mg, and a 2mm derma roller for hair loss but feels discouraged by the lack of results after a month. They are seeking advice and considering additional methods like antiandrogens, exercise, and dietary changes.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The user reports some hair regrowth after 12 weeks using 5% topical Minoxidil, 0.015% topical finasteride, and occasional microneedling. They also take multivitamins including biotin, though others suggest these are only effective if deficient.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

The conversation discusses the use of AlphaInfuse, a micro-infusion system with Panax ginseng and Eclipta prostrata extracts, for hair growth and its comparison to Minoxidil. The original poster seeks personal experiences and evidence of its effectiveness.